ClinicalTrials.gg
Not yet recruitingNCT07951112Updated Nov 20, 2026

DN-tTIS for Post-Stroke Motor Recovery

An interventional study of Temporal Interference Stimulation in Stroke and TI, sponsored by Tongji Hospital. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Tongji Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This study aims to explore a new, non-invasive treatment to help patients recover upper limb motor function after a stroke. Many stroke survivors experience long-term movement difficulties, and standard physical therapies may not always be effective, especially for those with severe motor impairments. Previous research suggests that stimulating a specific deep brain region called the cerebellar dentate nucleus can promote motor recovery, but traditional methods require invasive surgery.

In this study, researchers will investigate a novel technology called Temporal Interference (TI) electrical stimulation. TI allows researchers to safely and painlessly stimulate deep brain areas from the scalp without any surgery or implanted electrodes. The research team will enroll 10 patients who experienced a stroke 1 to 3 years ago and still have moderate to severe upper limb weakness. Participants will receive TI stimulation therapy 5 times a week for 4 weeks. Before, during, and after the treatment period, the researchers will use clinical physical assessments, brain imaging (fMRI), and non-invasive brain monitoring (EEG and fNIRS) to evaluate whether this treatment is safe, feasible, and effective for improving upper limb movement in chronic stroke survivors.

02

Conditions studied

  • Stroke
  • TI

Browse trials for

03

In context

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

This study's planned enrollment of 10 is below the median of 48 across 6,049 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

Tongji Hospital is the lead sponsor of 392 studies on the registry; 213 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • * Meets the diagnostic criteria for "stroke" in the "Key Points for Diagnosis of Major Cerebrovascular Diseases in China 2019", and confirmed by cranial CT or MRI.

    • First-ever stroke, with a disease duration of 1 year to 3 years (inclusive).
    • Age between 18 and 70 years old (inclusive).
    • Ischemic stroke in the territory of the unilateral middle cerebral artery, without affecting the cerebellum, thalamus, and brainstem.
    • Stable medical and neurological conditions, as determined by the investigator based on medical history, physical, and neurological examinations.
    • Residual moderate to severe unilateral upper limb hemiplegia, defined as an Upper Extremity Fugl-Meyer Assessment (FMA-UE) score of ≤ 50 on the affected side.
    • A score of ≥ 1 in at least one of the following FMA-UE sub-items: elbow flexion, elbow extension, or finger grasp.
    • Modified Rankin Scale (mRS) score \< 4.
    • No spasticity or moderate spasticity in the affected limb, defined as a Modified Ashworth Scale (MAS) score \< 4 in any region of the affected limb (shoulder internal rotators and adductors, elbow flexors, wrist flexors, or finger flexors).
    • (MMSE) score ≥ 24.

Exclusion criteria

Exclusion Criteria:

  • Primary hemorrhagic stroke or severe hemorrhagic transformation.

    • Presence of any other progressive neurological or somatic diseases impairing the target limb function, other than stroke.
    • Moderate to severe unilateral spatial neglect or anosognosia involving the affected side of the body.
    • Presence of any other neurological diseases that may compromise the safety of study participation, including central nervous system vasculitis, intracranial tumors, intracranial aneurysms, multiple sclerosis, or arteriovenous malformations.
    • Pain in the affected limb, defined as a pain score of ≥ 5 on the 0-10 Numeric Rating Scale (NRS).
    • Severe sensory impairment, demonstrated by a score of 2 on the National Institutes of Health Stroke Scale (NIHSS) sensory item (Item 8).
    • Occurrence of seizures since the stroke, regardless of the use of antiepileptic drugs.
    • Diagnosis of underlying seizure disorder or epilepsy.
    • Changed the dose of oral anti-spasticity medications within 2 weeks prior to study consent, or received botulinum toxin injections in the affected arm within 4 months prior to study consent, and/or plans to start anti-spasticity medications or botulinum toxin injections during the study follow-up period.
    • Presence of major active psychiatric illnesses that may interfere with treatment, such as psychotic disorders or severe personality disorders.
    • Untreated or inadequately treated depression, defined as a Beck Depression Inventory-II (BDI-II) score of ≥ 20 at enrollment.
    • Diagnosis of dementia.
    • Chronic uncontrolled hypertension, or a history of severe and uncontrolled cardiovascular disease.
    • to Magnetic Resonance Imaging (MRI), such as body weight incompatible with the scanner, or implanted metallic/electronic devices (pacemakers, defibrillators, spinal cord stimulators, etc.).
    • Presence of severe and poorly controlled medical conditions which, in the opinion of the Principal Investigator (PI), would pose an expected risk higher than that of the general stroke population.
    • Currently participating in another device, biologic, or drug study, or has not completed one within 30 days prior to consenting to this study.
    • Pregnancy (women of must use acceptable methods of ).
    • History of hemicraniectomy.
    • History of cerebrovascular stent implantation.
    • Presence of significant chronic small vessel ischemic disease, vertebrobasilar vascular disease, and/or any other structural abnormalities in the cerebellum, cerebellar peduncles, or brainstem.
    • Any other condition that, in the opinion of the investigator, would significantly increase the risk of interfering with study compliance, safety, or outcomes.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Experimental: tTIS Intervention Group

    All enrolled patients with chronic stroke will be assigned to this single arm to receive non-invasive temporal interference electrical stimulation (tTIS) therapy.

    Device: Temporal Interference Stimulation

Interventions

  • DeviceTemporal Interference Stimulation

    Patients will receive non-invasive temporal interference electrical stimulation targeting the contralateral cerebellar dentate nucleus. The stimulation is delivered with a total current of 6 mA. The treatment is administered 5 times a week for 4 consecutive weeks. Each treatment day includes two 40-minute tTIS sessions.

06

What researchers measure

Primary outcomes

  1. The safety of the tTIS intervention

    Safety will be evaluated by monitoring the incidence of adverse events (AEs), serious adverse events (SAEs), serious adverse device effects (SADEs), and unanticipated adverse device effects (UADEs) throughout the study period. An adverse event is defined as any untoward medical occurrence associated with the use of the intervention. A lower incidence (fewer participants experiencing AEs) indicates a better safety profile and therefore a better outcome.

    Time frame: Up to 4 weeks(from baseline to the end of treatment)

Secondary outcomes

  1. Change from baseline in Upper Extremity Fugl-Meyer Assessment (FMA-UE) Score

    Upper limb motor function was assessed using the Upper Extremity Subscale of the Fugl-Meyer Assessment (FMA-UE), which has a total score range of 0 to 66. In this scale, a higher score indicates better upper limb motor function and therefore a better outcome, with 0 representing severe motor impairment and 66 representing normal motor function. Changes in the score reflect the degree of improvement in upper limb motor function.

    Time frame: Baseline, Week 1, Week 2, Week 3, and Week 4

  2. Change from baseline in Action Research Arm Test (ARAT) Score

    Upper limb functional limitation and dexterity were assessed using the Action Research Arm Test (ARAT), which has a total score range of 0 to 57. In this scale, a higher score indicates better arm motor function and therefore a better outcome, with 0 representing no movement possible and 57 representing normal performance. Changes in the score reflect the degree of improvement in upper limb function.

    Time frame: Baseline, Week 1, Week 2, Week 3, and Week 4

  3. Change from baseline in Lower Extremity Fugl-Meyer Assessment (FMA-LE) Score

    Lower limb motor function was assessed using the Lower Extremity Subscale of the Fugl-Meyer Assessment (FMA-LE), which has a total score range of 0 to 34. In this scale, a higher score indicates better lower limb motor function and therefore a better outcome, with 0 representing severe motor impairment and 34 representing normal motor function. Changes in the score reflect the degree of improvement in lower limb motor function.

    Time frame: Baseline, Week 1, Week 2, Week 3, and Week 4

  4. Change from baseline in Berg Balance Scale (BBS) Score

    Static and dynamic balance abilities were assessed using the Berg Balance Scale (BBS), which has a total score range of 0 to 56. In this scale, a higher score indicates better balance function and therefore a better outcome, with 0 representing severely impaired balance and 56 representing excellent balance. Changes in the score reflect the degree of improvement in balance and fall risk reduction.

    Time frame: Baseline, Week 1, Week 2, Week 3, and Week 4

  5. Change from baseline in Modified Barthel Index (MBI)

    The patient's performance in activities of daily living was assessed using the Modified Barthel Index (MBI), which has a total score range of 0 to 100. In this scale, a higher score indicates a higher degree of independence in daily life and therefore a better outcome, with 0 representing complete dependence and 100 representing complete independence. Changes in the score reflect the degree of improvement in daily living abilities.

    Time frame: Baseline and Week 4

  6. Change from baseline in Modified Ashworth Scale (MAS) Score

    Muscle spasticity was assessed using the Modified Ashworth Scale (MAS), which has a total score range of 0 to 4 (scored as 0, 1, 1+, 2, 3, 4). In this scale, a higher score indicates greater severity of muscle spasticity and therefore a worse outcome, with 0 representing no increase in muscle tone and 4 representing the affected part being rigid in flexion or extension. Changes in the score reflect the degree of improvement in muscle spasticity.

    Time frame: Baseline, Week 1, Week 2, Week 3, and Week 4

  7. Change from baseline in Brunnstrom Recovery Stages

    The motor recovery process after stroke was assessed using the Brunnstrom Motor Recovery Stages, which classifies recovery into a range of Stage I to Stage VI (mapped to scores 1 to 6). In this scale, a higher stage indicates better voluntary motor control and therefore a better outcome, with Stage I representing flaccidity (no voluntary movement) and Stage VI representing near-normal joint movements. Changes in the stage reflect the progression of motor recovery.

    Time frame: Baseline, Week 1, Week 2, Week 3, and Week 4

  8. Change from baseline in Mini-Mental State Examination (MMSE) Score

    Cognitive function was assessed using the Mini-Mental State Examination (MMSE), which has a total score range of 0 to 30. In this scale, a higher score indicates better cognitive performance and therefore a better outcome, with 0 representing severe cognitive impairment and 30 representing normal cognition. Changes in the score reflect the degree of improvement in cognitive function.

    Time frame: Baseline and Week 4

  9. Change from baseline in Montreal Cognitive Assessment (MoCA) Score

    Mild cognitive dysfunction was assessed using the Montreal Cognitive Assessment (MoCA), which has a total score range of 0 to 30. In this scale, a higher score indicates better cognitive performance and therefore a better outcome, with 0 representing severe cognitive impairment and 30 representing normal cognition. Changes in the score reflect the degree of improvement in cognitive function.

    Time frame: Baseline and Week 4

  10. Change from baseline in Hamilton Depression Rating Scale (HAMD) Score

    The severity of depressive symptoms was assessed using the 17-item Hamilton Depression Rating Scale (HAMD-17), which has a total score range of 0 to 52. In this scale, a higher score indicates greater severity of depression and therefore a worse outcome, with 0 representing no depression and 52 representing the most severe depression. Changes in the score reflect the degree of improvement in depressive symptoms.

    Time frame: Baseline and Week 4

  11. Change from baseline in Hamilton Anxiety Rating Scale (HAMA) Score

    The severity of anxiety symptoms was assessed using the Hamilton Anxiety Rating Scale (HAMA), which has a total score range of 0 to 56. In this scale, a higher score indicates greater severity of anxiety and therefore a worse outcome, with 0 representing no anxiety and 56 representing the most severe anxiety. Changes in the score reflect the degree of improvement in anxiety symptoms.

    Time frame: Baseline and Week 4

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Baker KB, Plow EB, Nagel S, Rosenfeldt AB, Gopalakrishnan R, Clark C, Wyant A, Schroedel M, Ozinga J 4th, Davidson S, Hogue O, Floden D, Chen J, Ford PJ, Sankary L, Huang X, Cunningham DA, DiFilippo FP, Hu B, Jones SE, Bethoux F, Wolf SL, Chae J, Machado AG. Cerebellar deep brain stimulation for chronic post-stroke motor rehabilitation: a phase I trial. Nat Med. 2023 Sep;29(9):2366-2374. doi: 10.1038/s41591-023-02507-0. Epub 2023 Aug 14. PubMed 37580534 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jan 2027, 1 month later.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 1 month is below that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2026
First posted
Nov 20, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 15, 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951112
Lead sponsor
Tongji Hospital
Responsible party
Tang Zhouping (Professor, Tongji Hospital) — Principal investigator
First posted
Nov 20, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 15, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Xinran Xu
Contact
xuxinran0306@163.com
86+13971176866

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion